Pooling 14 placebo-controlled trials (76,969 adults with type 2 diabetes), SGLT2 inhibitors lowered the composite of first heart failure hospitalization or cardiovascular death by 23% (HR 0.77, 95% CI 0.73-0.81; I2 = 0%). Heart failure hospitalization fell 29%, composite kidney outcomes 31%, cardiovascular death 14%, and myocardial infarction 12%. Stroke showed no significant change (HR 0.93, 0.81-1.08). Benefit did not differ by baseline heart failure or established atherosclerotic disease.
The headline numbers confirm what the landmark trials (EMPA-REG, CANVAS, DECLARE, CREDENCE, DAPA-CKD) already suggested, so this is consolidation rather than a new discovery. The practical message is the null interaction results: people with diabetes but no prior heart disease or heart failure appeared to benefit similarly, which supports considering these drugs well beyond secondary prevention. The absence of any stroke benefit is a useful reality check, since these agents act mainly through hemodynamic and kidney-protective pathways rather than by lowering glucose. Caveats matter: the pooled trials were industry-sponsored, kidney endpoints were defined differently across studies and showed moderate heterogeneity, and ertugliflozin's weaker estimate suggests the effect may not be perfectly uniform across the class. Trial-level analysis also cannot identify which individuals benefit most. Anyone with type 2 diabetes, particularly with kidney impairment or heart failure risk, has solid grounds to discuss these drugs with their doctor, weighing genital infections and volume depletion.